Search

Displaying results 1681 - 1690 of 3601 in total
  1. Drug

    Itruvone

    go.drugbank.com/drugs/DB21543
    Investigational

    Itruvone is under investigation in clinical trial NCT02322086 (A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10).

  2. Drug

    Pagoclone

    go.drugbank.com/drugs/DB04903
    Investigational

    Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbe...

  3. Drug

    Hydroxyproline

    go.drugbank.com/drugs/DB08847
    Approved

    Hydroxyproline is a neutral heterocyclic protein amino acid. It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis. Therapeutic...

    Mixtures: Cathycat Chewy CREAM FOUNDATION SPF23 PA WHITENING ANTI WRINKLE 21, Cathycat Chewy CREAM FOUNDATION SPF23 PA WHITENING ANTI WRINKLE 23
  4. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound

  5. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  6. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    Congenital loss or deficiency of Factor VIII results in the physiologic impairment of the coagulation clotting cascade, and as a result, leads to easy bruising and bleeding. … Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein.

    Mixtures: Monoclate-P, Humate-PProducts: Monoclate-P, Haemate P 250 I.E. FVIII / 600 I.E. VWF Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung. Haemate P 500 I.E. FVIII / 1200 I.E.
  7. Drug

    Oleic Acid

    go.drugbank.com/drugs/DB04224
    ApprovedInvestigationalVet approved

    An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)

    Mixtures: NEUROGAIN PB VEGICAP CAPSULE 500MG
  8. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  9. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

  10. Drug

    Upleganan

    go.drugbank.com/drugs/DB21618
    Investigational

    Upleganan is under investigation in clinical trial NCT04865393 (Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function).